3 weeks Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst SaysMarketBeat
Guggenheim boosted their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday.
X